文献速递肿瘤 PET/CT

四种68Ga标记多聚RGD肽在两种人肿瘤异种移植小鼠模型中显像αvβ3整合素表达的体内特征比较

In Vivo Characterization of 4 68Ga-Labeled Multimeric RGD Peptides to Image αvβ3 Integrin Expression in 2 Human Tumor Xenograft Mouse Models.
PubMed 文献 · J Nucl Med · 2018-04-06

研究比较了4种68Ga标记的多聚环状RGD示踪剂在αvβ3整合素阳性SK-RC-52肿瘤模型和αvβ3整合素仅表达于新生血管的FaDu肿瘤模型中的靶向特征。小动物PET/CT显像和离体生物分布显示各示踪剂在两种模型中均有特异性肿瘤摄取,68Ga-FSC-(RGD)3在SK-RC-52模型中肿瘤摄取显著高于其他三种示踪剂,但在FaDu模型中并非如此。作者结论认为所有示踪剂均能实现肿瘤检测,最佳示踪剂选择还需考虑肿瘤/血比值和正常组织摄取。

要点

  • 四种68Ga标记多聚RGD示踪剂在两种肿瘤模型中均显示特异性摄取,可实现肿瘤检测。
  • 68Ga-FSC-(RGD)3在SK-RC-52模型中肿瘤摄取显著高于其他三种示踪剂。
  • FaDu模型中68Ga-FSC-(RGD)3肿瘤摄取显著高于68Ga-TRAP-(RGD)3。

核心结论

  • 所有示踪剂均显示足够的αvβ3整合素靶向能力以实现肿瘤检测。
  • SK-RC-52模型中68Ga-FSC-(RGD)3肿瘤摄取最高,FaDu模型中68Ga-THP-(RGD)3肿瘤摄取最高。
  • 特定诊断应用的最佳示踪剂选择还取决于肿瘤/血比值和正常组织摄取,这些因素也应予以考虑。

研究设计与样本

  • 雌性BALB/c裸鼠皮下注射SK-RC-52(αvβ3整合素阳性)或FaDu(αvβ3整合素阴性)肿瘤细胞。
  • 静脉给予68Ga标记的DOTA-(RGD)2、TRAP-(RGD)3、FSC-(RGD)3或THP-(RGD)3(每只小鼠0.5 nmol,10-20 MBq)。
  • 注射后1小时行小动物PET/CT显像和离体生物分布研究。
  • 通过共注射过量未标记DOTA-(RGD)2(50 nmol)确定两种模型中的非特异性摄取。

主要发现

  • 显像和生物分布数据显示每种示踪剂在两种模型中均有肿瘤特异性摄取。
  • SK-RC-52模型中68Ga-FSC-(RGD)3肿瘤摄取显著高于68Ga-DOTA-(RGD)2、68Ga-TRAP-(RGD)3或68Ga-THP-(RGD)3。
  • FaDu模型中68Ga-FSC-(RGD)3肿瘤摄取未显著高于68Ga-DOTA-(RGD)2、68Ga-TRAP-(RGD)3或68Ga-THP-(RGD)3。
  • FaDu模型中68Ga-FSC-(RGD)3肿瘤摄取显著高于68Ga-TRAP-(RGD)3。
  • 正常组织和肿瘤/血比值中也观察到差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

αvβ3 integrins play an important role in angiogenesis and cell migration in cancer and are highly expressed on the activated endothelial cells of newly formed blood vessels. Here, we compare the targeting characteristics of 4 68Ga-labeled multimeric cyclic arginine-glycine-aspartate (RGD)-based tracers in an αvβ3 integrin-expressing tumor model and a tumor model in which αvβ3 integrin is expressed solely on the neovasculature. Methods: Female BALB/c nude mice were subcutaneously injected with SK-RC-52 (αvβ3 integrin-positive) or FaDu (αvβ3 integrin-negative) tumor cells. 68Ga-labeled DOTA-(RGD)2, TRAP-(RGD)3, FSC-(RGD)3, or THP-(RGD)3 was intravenously administered to the mice (0.5 nmol per mouse, 10-20 MBq), followed by small-animal PET/CT imaging and ex vivo biodistribution studies 1 h after injection. Nonspecific uptake of the tracers in both models was determined by coinjecting an excess of unlabeled DOTA-(RGD)2 (50 nmol) along with the radiolabeled tracers. Results: Imaging and biodistribution data showed specific uptake in the tumors for each tracer in both models. Tumor uptake of 68Ga-FSC-(RGD)3 was significantly higher than that of 68Ga-DOTA-(RGD)2, 68Ga-TRAP-(RGD)3, or 68Ga-THP-(RGD)3 in the SK-RC-52 model but not in the FaDu model, in which 68Ga-FSC-(RGD)3 showed significantly higher tumor uptake than 68Ga-TRAP-(RGD)3 Most importantly, differences were also observed in normal tissues and in tumor-to-blood ratios. Conclusion: All tracers showed sufficient targeting of αvβ3 integrin expression to allow for tumor detection. Although the highest tumor uptake was found for 68Ga-FSC-(RGD)3 and 68Ga-THP-(RGD)3 in the SK-RC-52 and FaDu models, respectively, selection of the optimal tracer for specific diagnostic applications also depends on tumor-to-blood ratio and uptake in normal tissues; these factors should therefore also be considered.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lobeek D, Franssen GM, Ma MT, et al. In Vivo Characterization of 4 68Ga-Labeled Multimeric RGD Peptides to Image αvβ3 Integrin Expression in 2 Human Tumor Xenograft Mouse Models. J Nucl Med. 2018. PMID: 29626124. doi:10.2967/jnumed.117.206979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。